Assessing the Effect of Using Solifenacin 5 mg Versus Mirabegron 50 mg in Treatment of Overactive Bladder: A Comparative Study | ||||
| Minia Journal of Medical Research | ||||
| Articles in Press, Accepted Manuscript, Available Online from 03 August 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2025.401685.2021 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ahmed Mohamed Abdelmalek1; Mohamed Hamdy Mohamed Abo Elhassan2; Ali Abdelwahab Mohammed  3; mohamed gamal Hasanein4
| ||||
| 1urology department , faculty of medicine , Elmina university , Egypt | ||||
| 2Urology Department, Faculty of Medicine, Minia University, Minia, Egypt | ||||
| 3Urology Department , Faculty of Medicine, Minia University, Minia, Egypt | ||||
| 4Urology department faculty of medecine minia university | ||||
| Abstract | ||||
| Introduction: Overactive bladder (OAB) is a chronic condition affecting men and women, particularly those over 40, with prevalence rates in Europe and the U.S.and over 33 million cases in the U.S. A 2021 study found 49-58.5% prevalence in Middle Eastern countries. Aim of the work:To compare the effect of Solifenacin 5mg vrsus Mirabegron50 mg to in the treating overactive bladder(OAB)Patients and Methods: prospective,randomized,open-label study was conducted at Minia Urology and Nephrology University Hospital in Egypt over six months. The study involved 60 patients with primary overactive bladder aged 12-65 years, of both sexes. Patients were excluded if they refused consent, were under 12 or over 65 years, had liver disease, closed-angle glaucoma, stress incontinence, neurological detrusor issues,contraindications to study drugs, prior voiding dysfunction surgeries, or failed prior medical treatment.Patients were randomly assigned to two groups: one received daily oral Solifenacin 5 mg, and the other received daily Mirabegron 50 mg. All participants were evaluated and followed up at different intervals. Results: A study comparing Solifenacin and Mirabegron for overactive bladder treatment found similar baseline characteristics between the two groups.By 12 weeks, Mirabegron showed significant improvements in all OAB symptoms, including urgency, urge incontinence, incontinence, and frequency of micturition, indicating treatment effects rather than confounding factors. Conclusion : Mirabegron 50 mg monotherapy proved more effective than Solifenacin 5mg monotherapy in treating overactive bladder (OAB), with Solifenacin showing the least improvement in symptom scores. Micturition frequency responded best to treatment,while nocturia showed the least improvement, highlighting varied treatment effects on OAB symptoms. | ||||
| Keywords | ||||
| Overactive bladder; National Overactive Bladder Evaluation Program; International Continence Society | ||||
|
Statistics Article View: 39 |
||||
